Top in hem/onc: Cell therapy approaches; low colorectal cancer screening rates
Click Here to Manage Email Alerts
Strategies for cell therapy to treat cancer very depending on the type of tumor, according to experts.
At this year’s American Association for Cancer Research Annual Meeting, three presentations illustrated how different approaches can enhance the effectiveness of cell therapies for blood cancers or solid tumors. A review of the research was the top story in hematology/oncology last week.
The second top story was about low colorectal cancer screening rates in the United States among younger adults. In 2018, individuals aged 70 to 75 years had a 78% screening prevalence while those aged 50 to 54 years had a 47.6% screening prevalence.
Read these and more top stories in hematology/oncology below:
Novel approaches highlight potential of cell therapy for a wider array of cancers
The ideal strategy to treat cancer with cell therapy can vary greatly depending on tumor type. On one hand, outcomes for patients with hematologic malignancies might be improved by modifying current chimeric antigen receptor T-cell therapy constructs. On the other, the complexity of treating solid tumors may require combination strategies to enhance effectiveness. Read more.
Colorectal cancer screening prevalence remains low among younger adults
Colorectal cancer screening prevalence remained low in 2018 among U.S. adults aged 50 to 54 years vs. 70 to 75 years, with the younger group exhibiting larger disparities by race/ethnicity, education level, income and insurance. Read more.
Personality traits, social norms may contribute to gender wage gap
Although personality traits and social norms appeared to be key factors in the gender wage gap, their precise contributions were unclear, according to study results published in Journal of Economic Surveys. Read more.
Oncolytic adenovirus shows potential in pediatric diffuse intrinsic pontine glioma
The oncolytic adenovirus DNX-2401 (DNAtrix) appeared to be safe and feasible among a small cohort of pediatric patients with diffuse intrinsic pontine glioma, according to study results published in The New England Journal of Medicine. Read more.
FDA warns about potential elevated risk for death with blood cancer therapy durvelisib
The FDA issued a warning about a potentially increased risk for death or serious adverse effects with Copiktra (durvelisib, Secura Bio) an approved blood cancer therapy. Read more.